These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 31623877)

  • 21. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?
    Park KT; Kang DH; Choi CW; Cho M; Park SB; Kim HW; Kim DU; Chung CW; Yoon KT
    Pancreas; 2011 Nov; 40(8):1215-9. PubMed ID: 21775918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection.
    Shimada M; Matsumata T; Shirabe K; Kamakura T; Taketomi A; Sugimachi K
    J Am Coll Surg; 1994 May; 178(5):498-502. PubMed ID: 8167888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe abdominal pain associated with allergic reaction to nafamostat mesilate in a chronic hemodialysis patient.
    Yamazato M; Mano R; Oshiro-Chinen S; Tomiyama N; Sakima A; Ishida A; Tana T; Tozawa M; Muratani H; Iseki K; Takishita S
    Intern Med; 2002 Oct; 41(10):864-6. PubMed ID: 12413011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Corrigendum to "Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals" [Cancer Lett. 386 (2017) 12-23].
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2018 Feb; 414():310. PubMed ID: 29097156
    [No Abstract]   [Full Text] [Related]  

  • 25. Corrigendum to "Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals"[Cancer Lett. 386 (2017)12-23].
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2021 Feb; 498():251-252. PubMed ID: 32859427
    [No Abstract]   [Full Text] [Related]  

  • 26. Nafamostat mesilate is an extremely potent inhibitor of human tryptase.
    Mori S; Itoh Y; Shinohata R; Sendo T; Oishi R; Nishibori M
    J Pharmacol Sci; 2003 Aug; 92(4):420-3. PubMed ID: 12939527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Randomized Comparative Study of 24- and 6-Hour Infusion of Nafamostat Mesilate for the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective Randomized Comparison Trial.
    Kim SJ; Kang DH; Kim HW; Choi CW; Park SB; Song BJ; Nam HS
    Pancreas; 2016 Sep; 45(8):1179-83. PubMed ID: 27253231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipocalin2 suppresses metastasis of colorectal cancer by attenuating NF-κB-dependent activation of snail and epithelial mesenchymal transition.
    Feng M; Feng J; Chen W; Wang W; Wu X; Zhang J; Xu F; Lai M
    Mol Cancer; 2016 Dec; 15(1):77. PubMed ID: 27912767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nafamostat mesilate, a serine protease inhibitor, suppresses lipopolysaccharide-induced nitric oxide synthesis and apoptosis in cultured human trophoblasts.
    Nakatsuka M; Asagiri K; Noguchi S; Habara T; Kudo T
    Life Sci; 2000; 67(10):1243-50. PubMed ID: 10954057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Marked eosinophilia induced by nafamostat mesilate, an anticoagulant in a hemodialysis patient.
    Nakanishi K; Kaneko T; Yano F; Horio M; Kawagoe H; Fujii M; Kashiwai K
    Nephron; 1992; 62(1):97-9. PubMed ID: 1436301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
    Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
    Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nafamostat mesilate negatively regulates the metastasis of triple-negative breast cancer cells.
    Mander S; You DJ; Park S; Kim DH; Yong HJ; Kim DS; Ahn C; Kim YH; Seong JY; Hwang JI
    Arch Pharm Res; 2018 Feb; 41(2):229-242. PubMed ID: 29196918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats.
    Li C; Wang J; Fang Y; Liu Y; Chen T; Sun H; Zhou XF; Liao H
    Brain Behav Immun; 2016 Aug; 56():230-45. PubMed ID: 27033633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma.
    Chen CL; Wang SD; Zeng ZY; Lin KJ; Kao ST; Tani T; Yu CK; Wang JY
    J Allergy Clin Immunol; 2006 Jul; 118(1):105-12. PubMed ID: 16815145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aprotinin and nafamostat mesilate in liver surgery: effect on blood loss.
    Pereboom IT; de Boer MT; Porte RJ; Molenaar IQ
    Dig Surg; 2007; 24(4):282-7. PubMed ID: 17657153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Corrigendum to "Activation of adenosine A3 receptor suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of PI 3-kinase/Akt and NF-kappaB activation in murine BV2 microglial cells" [Neurosci. Lett. 396 (2006):1-6].
    Lee JY; Jhun BS; Oh YT; Lee JH; Choe W; Baik HH; Ha J; Yoon KS; Kim SS; Kang I
    Neurosci Lett; 2019 Nov; 712():134486. PubMed ID: 31526548
    [No Abstract]   [Full Text] [Related]  

  • 38. Olfactomedin 1 negatively regulates NF-κB signalling and suppresses the growth and metastasis of colorectal cancer cells.
    Shi W; Ye Z; Zhuang L; Li Y; Shuai W; Zuo Z; Mao X; Liu R; Wu J; Chen S; Huang W
    J Pathol; 2016 Nov; 240(3):352-365. PubMed ID: 27555280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of nafamostat mesilate on serum activities of pancreatic enzymes and plasma hormone levels].
    Wakayama S; Suzuki T; Sakai T; Matsuki A
    Masui; 1990 Jun; 39(6):734-40. PubMed ID: 2388392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corrigendum to "Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-κB pathway" [Canc. Lett. 342 (2014) 150-158].
    Zhao Z; Wu MS; Zou C; Tang Q; Lu J; Liu D; Wu Y; Yin J; Xie X; Shen J; Kang T; Wang J
    Cancer Lett; 2021 Dec; 522():281. PubMed ID: 34561145
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.